Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To evaluate the safety and tolerability of QVA149 27.5/12.5 μg b.i.d. and QVA149 27.5/25 μg b.i.d. in terms of adverse event reporting rate in patients with Chronic Obstructive Pulmonary Disease (COPD) with moderate to severe airflow limitation during 52 weeks of treatment.
Inclusion criteria
- Chronic Obstructive Pulmonary Disease (COPD)